Can-Fite BioPharma (CANF) News Today $2.04 -0.11 (-5.12%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Can-Fite BioPharma (NYSE:CANF) Downgraded to Sell Rating by StockNews.comOctober 31 at 4:59 AM | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Upgraded to Hold by StockNews.comOctober 23, 2024 | americanbankingnews.comCan Fite Biofarma (AMEX:CANF) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comSignificant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonOctober 18, 2024 | globenewswire.comCan-Fite BioPharma Rises 17% After Pancreatic-Cancer Drug Gets Orphan DesignationOctober 9, 2024 | marketwatch.comFDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerOctober 9, 2024 | markets.businessinsider.comFDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic CancerOctober 9, 2024 | globenewswire.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29October 7, 2024 | finance.yahoo.comCan-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthSeptember 16, 2024 | globenewswire.comCan-Fite reports H1 financials, clinical progressAugust 30, 2024 | investing.comIs Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?August 30, 2024 | msn.comCan-Fite BioPharma Ltd.: Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAugust 29, 2024 | finanznachrichten.deCan-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAugust 29, 2024 | globenewswire.comOS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVAugust 9, 2024 | finanznachrichten.deCan-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAugust 8, 2024 | globenewswire.comCan-Fite BioPharma Ltd.: Can-Fite Provides Namodenoson Patent UpdateJuly 29, 2024 | finanznachrichten.deCan-Fite Provides Namodenoson Patent UpdateJuly 29, 2024 | globenewswire.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8July 17, 2024 | globenewswire.comCan-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerJuly 11, 2024 | globenewswire.comCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverJune 24, 2024 | businesswire.comCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyJune 10, 2024 | businesswire.comCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyJune 5, 2024 | businesswire.comIndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart DiseasesMay 29, 2024 | businesswire.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 27, 2024 | finance.yahoo.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 27, 2024 | businesswire.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6May 23, 2024 | finance.yahoo.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6May 23, 2024 | businesswire.comCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyMay 13, 2024 | businesswire.comCan-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMay 10, 2024 | finanznachrichten.deBuy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study OutlookMay 10, 2024 | markets.businessinsider.comCan-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602May 6, 2024 | businesswire.comLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalApril 25, 2024 | businesswire.comCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHApril 15, 2024 | businesswire.comCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsApril 3, 2024 | businesswire.comCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical UpdateMarch 28, 2024 | finanznachrichten.deNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceMarch 11, 2024 | businesswire.comCan-Fite secures Canadian patent for liver disease drugMarch 1, 2024 | investing.comCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaFebruary 28, 2024 | businesswire.comHistorical PricesFebruary 24, 2024 | wsj.comCan-Fite BioPharma Ltd. (CANF)February 22, 2024 | finance.yahoo.comBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical ProspectsFebruary 8, 2024 | markets.businessinsider.comCan Fite Biopharma Ltd (CANF)January 30, 2024 | investing.comCan Fite Biopharma Ltd ADR (CANF)January 30, 2024 | investing.comCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationJanuary 30, 2024 | finance.yahoo.comCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyJanuary 29, 2024 | finance.yahoo.comThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesDecember 20, 2023 | finance.yahoo.comCan-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick FactsDecember 18, 2023 | markets.businessinsider.comCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanDecember 18, 2023 | finance.yahoo.comCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentDecember 4, 2023 | finance.yahoo.comCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateNovember 30, 2023 | finance.yahoo.com Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here CANF Media Mentions By Week CANF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CANF News Sentiment▼0.000.41▲Average Medical News Sentiment CANF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CANF Articles This Week▼11▲CANF Articles Average Week Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Natural Alternatives International News MIRA Pharmaceuticals News ImmuCell News MiNK Therapeutics News Iterum Therapeutics News Pluri News Lisata Therapeutics News BioXcel Therapeutics News BioVie News Bright Green News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CANF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
